ArticleInternational journal of nanomedicine2017
Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 59 citations in OpenAlex.
- Recent Advances in Nanoparticle-Mediated Antibacterial Photodynamic Therapy.International journal of molecular sciences · 2025Review
- Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.Antioxidants (Basel, Switzerland) · 2025Review
- Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment.Redox biology · 2025Review
- Photodynamic Therapy: Past, Current, and Future.International journal of molecular sciences · 2024Review
- Magnetic nanoparticles and possible synergies with cold atmospheric plasma for cancer treatment.RSC advances · 2024Review
- Antimicrobial Photodynamic Therapy Using Encapsulated Protoporphyrin IX for the Treatment of Bacterial Pathogens.Materials (Basel, Switzerland) · 2024Article
- Nanotechnology as a Promising Method in the Treatment of Skin Cancer.International journal of molecular sciences · 2024Review
- Increased radiosensitivity of melanoma cells through cold plasma pretreatment mediated by ICG.Journal of radiation research · 2023Article
- Combinations of Photodynamic Therapy with Other Minimally Invasive Therapeutic Technologies against Cancer and Microbial Infections.International journal of molecular sciences · 2023Review
- A PPIX-binding probe facilitates discovery of PPIX-induced cell death modulation by peroxiredoxin.Communications biology · 2023Article
- The Synergistic Effect of Cold Atmospheric Plasma Mediated Gold Nanoparticles Conjugated with Indocyanine Green as An Innovative Approach to Cooperation with Radiotherapy.Cell journal · 2023Article
- Applications of Antimicrobial Photodynamic Therapy against Bacterial Biofilms.International journal of molecular sciences · 2022Review
- Review
- Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma.Frontiers in oncology · 2022Review
- Plasma Dermatology: Skin Therapy Using Cold Atmospheric Plasma.Frontiers in oncology · 2022Review
- Melanoma and Nanotechnology-Based Treatment.Frontiers in oncology · 2022Review
- Role of Short- and Long-Lived Reactive Species on the Selectivity and Anti-Cancer Action of Plasma Treatment In Vitro.Cancers · 2021Article
- Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity.Oxidative medicine and cellular longevity · 2021Review
- Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery.Advances in cancer research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional cancer treatments contain several limitations such as incomplete ablation and multidrug resistance. It is known that photodynamic therapy (PDT) is an effective treatment for several tumor types especially melanoma cells. During the PDT process, protoporphyrin IX (PpIX), an effective photosensitizer, can selectively kill cancer cells by activating a special light source. When tumor cells encapsulate a photosensitizer, they can be easily excited into an excited state by a light source. In this study, cold atmospheric plasma (CAP) was used as a novel light source. Results of some studies have showed that cancer cells can be effectively killed by using either a light source or an individual treatment due to the generation of reactive oxygen species and electrons from a wide range of wavelengths, which suggest that CAP can act as a potential light source for anticancer applications compared with UV light sources. Results of the present in vitro study indicated for the first time that PpIX can be successfully loaded into polymersomes. Most importantly, cell viability studies revealed that PpIX-loaded polymersomes had a low toxicity to healthy fibroblasts (20% were killed) at a concentration of 400 µg/mL, but they showed a great potential to selectively kill melanoma cells (almost 50% were killed). With the application of CAP posttreatment, melanoma cell viability significantly decreased (80% were killed) compared to not using a light source (45% were killed) or using a UV light source (65% were killed). In summary, these results indicated for the first time that PpIX-loaded polymersomes together with CAP posttreatment could be a promising tool for skin cancer drug delivery with selective toxicity toward melanoma cells sparing healthy fibroblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.